Neuropathix (NPTX) 10-Q 14 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 14, 2020
Document And Entity Information
Entity Registrant Name	Kannalife Inc
Entity Central Index Key	0001615999
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity's Reporting Status Current	Yes
Is Entity Emerging Growth?	true
Is Entity Small Business?	true
Entity Extended Transition Period?	false
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Incorporation, State or Country Code	DE
Entity File Number	000-55657
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		74,250,141
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 114,582	$ 121,455
Prepaid expenses	6,000	9,000
Other receivables	400	400
Total Current Assets	120,982	130,855
NON-CURRENT ASSETS:
Property and equipment, net	71,367	75,401
Security deposits	17,121	17,121
Total Non-Current Assets	88,488	92,522
TOTAL ASSETS	209,470	223,377
CURRENT LIABILITIES:
Accounts payable and accrued expenses	384,159	389,195
Payroll and related liabilities	273,510	243,208
Loan payable	620,000	620,000
Loan payable - related party	42,092	42,092
Convertible notes payable, net of $192,740 debt discount	17,260	0
Capital lease obligations	7,757	7,533
Due to related party, net	49,261	25,349
Derivative liabilities	194,350	0
Total Current Liabilities	1,588,389	1,327,377
LONG TERM LIABILITIES:
Convertible notes payable - long term, net of $85,205 debt discount	391,167	378,839
Convertible notes payable - long term, net of $135,479 debt discount - related party	14,521	0
Capital lease obligation - long term	25,739	27,764
Derivative liabilities - long term	191,540	183,451
Total Long Term Liabilities	622,967	590,054
TOTAL LIABILITIES	2,211,356	1,917,431
Commitments and contingencies	0	0
STOCKHOLDERS' DEFICIT:
Common stock, $0.0001 par value, 200,000,000 authorized, 74,225,141 issued and outstanding	7,422	7,422
Additional paid-in capital	6,794,612	6,794,612
Accumulated deficit	(8,803,920)	(8,496,088)
TOTAL STOCKHOLDERS' DEFICIT	(2,001,886)	(1,694,054)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	209,470	223,377
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized Series A preferred stock, 75 shares designated, 75 issued and outstanding (Liquidation preference of $75,000), Series B preferred stock, 75 shares designated, 75 issued and outstanding (Liquidation preference of $75,000)	0	0
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized Series A preferred stock, 75 shares designated, 75 issued and outstanding (Liquidation preference of $75,000), Series B preferred stock, 75 shares designated, 75 issued and outstanding (Liquidation preference of $75,000)	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Debt discount Current	$ 192,740
Debt discount non current	85,205
Debt discount - related party	$ 135,479
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	74,225,141	74,225,141
Common Stock, Shares, Outstanding	74,225,141	74,225,141
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized	75	75
Preferred Stock, Shares Issued	75	75
Preferred Stock, Shares Outstanding	75	75
Liquidation preference	$ 75,000	$ 75,000
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized	75	75
Preferred Stock, Shares Issued	75	75
Preferred Stock, Shares Outstanding	75	75
Liquidation preference	$ 75,000	$ 75,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
NET REVENUES:
Grant Revenue	$ 0	$ 49,291
TOTAL NET REVENUES	0	49,291
OPERATING EXPENSES:
Research and development	19,727	101,278
General and administrative	364,107	451,186
TOTAL OPERATING EXPENSES	383,834	552,464
LOSS FROM OPERATIONS	(383,834)	(503,173)
OTHER INCOME (EXPENSE):
Interest expense, net	(215,163)	(15,980)
Net gains and losses recognized on marketable security	0	(329,346)
Change in fair value of derivative liabilities	291,165	0
TOTAL OTHER INCOME (EXPENSE)	76,002	(345,326)
NET LOSS BEFORE INCOME TAX	(307,832)	(848,499)
Income tax expense	0	0
NET LOSS	(307,832)	(848,499)
Net loss attributable to noncontrolling interests	0	(2,534)
Net loss attributable to Kannalife, Inc.	$ (307,832)	$ (845,965)
Loss attributable to Kannalife, Inc. per common share - basic	$ 0	$ (0.01)
Loss attributable to Kannalife, Inc. per common share - diluted	$ 0	$ (0.01)
Weighted average common shares outstanding - basic	74,225,141	69,854,141
Weighted average common shares outstanding - diluted	74,225,141	69,854,141

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)	Series A Preferred Stock	Series B Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Noncontrolling Interest	Total
Beginning balance, Shares at Dec. 31, 2018	75	75	69,854,141
Beginning balance, Amount at Dec. 31, 2018			$ 6,985	$ 6,381,755	$ (5,052,051)	$ (5,756)	$ 1,330,933
Issuance of stock options for services				2,519			2,519
Net (loss) income					(845,965)	(2,534)	(848,499)
Ending balance, Shares at Mar. 31, 2019	75	75	69,854,141
Ending balance, Amount at Mar. 31, 2019			$ 6,985	6,384,274	(5,898,016)	(8,290)	484,953
Beginning balance, Shares at Dec. 31, 2019	75	75	74,225,141
Beginning balance, Amount at Dec. 31, 2019			$ 7,422	6,794,612	(8,496,088)		(1,694,054)
Net (loss) income					(307,832)		(307,832)
Ending balance, Shares at Mar. 31, 2020	75	75	74,225,141
Ending balance, Amount at Mar. 31, 2020			$ 7,422	$ 6,794,612	$ (8,803,920)		$ (2,001,886)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Cash Flows [Abstract]
Net loss	$ (307,832)	$ (848,499)
Adjustments to reconcile net loss to net cash used in operating activities:
Net gains and losses recognized on marketable security	0	329,346
Depreciation	4,034	152
Amortization of debt discount	44,109	0
Issuance of options for services	0	2,519
Non-cash interest expense	149,604	0
Change in fair value of derivative liabilities	(291,165)	0
Changes in operating assets and liabilities:
Prepaid expenses	3,000	0
Other receivables	0	50,000
Security deposits	0	(14,641)
Accounts payable and accrued expenses	(5,036)	0
Payroll and related liabilities	30,302	1,329
Due to related party, net	23,912	6,535
NET CASH USED IN OPERATING ACTIVITIES	(349,072)	(473,259)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of marketable securities	0	725,294
NET CASH PROVIDED BY INVESTING ACTIVITIES	0	725,294
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments toward capital lease obligations	(1,801)	0
Proceeds from convertible notes payable	194,000	0
Proceeds from convertible notes payable - related party	150,000	97
NET CASH PROVIDED BY FINANCING ACTIVITIES	342,199	97
Net (decrease) increase in cash	(6,873)	252,132
Cash and cash equivalents, beginning of period	121,455	307,131
Cash and cash equivalents, end of period	114,582	559,263
NON-CASH ACTIVITIES:
Debt discount upon the issuance of convertible note payable	194,000	0
Debt discount upon the issuance of convertible note payable - related party	$ 150,000	$ 0

Organization and Nature of Oper

Organization and Nature of Operations	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	Note 1 – Organization and Nature of Operations Kannalife, Inc. (the “Company”) was incorporated under the laws of the state of Delaware on March 25, 2013 under the name TYG Solutions Corp. The Company consummated a share exchange transaction on July 25, 2018 with Kannalife Sciences, Inc. (“Kannalife”), a privately held Delaware corporation formed in 2010, the accounting acquirer. Upon completion of the share exchange transaction, Kannalife is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Kannalife the surviving entity and accounting acquirer. All references that refer to (the “Company” or “we” or “us” or “our”) are Kannalife, unless otherwise differentiated. Kannalife is a phytomedical/pharmaceutical company that specializes in the research and development of synthetic molecules and therapeutic products derived from botanical sources, including the cannabis taxa. Name Change On November 9, 2018, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State that changed its name to Kannalife, Inc. The Company concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change. The Company’s name change and ticker symbol change was reviewed and processed by FINRA and went effective January 17, 2019. Unaudited Interim Financial Information We have prepared the accompanying condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These condensed consolidated financial statements are unaudited and, in our opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of our balance sheets, operating results, and cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for 2020. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been omitted in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with our audited financial statements and accompanying notes for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 30, 2020.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies The significant accounting policies used in the preparation of the condensed consolidated financial statements are as follows: Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Significant Risks and Uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. In December 2019, a novel strain of coronavirus surfaced. The spread of COVID-19 around the world in the first quarter of 2020 has caused significant volatility in U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations. The Company’s operations as of March 31, 2020 have not been affected, but may be affected in the future, by the recent and ongoing outbreak of the coronavirus disease 2019 (COVID-19) which in March 2020, was declared a pandemic by the World Health Organization. The ultimate disruption which may be caused by the outbreak is uncertain; however, it may result in a material adverse impact on the Company’s financial position, operations and cash flows. Possible areas that may be affected include, but are not limited to, disruption to the Company’s labor workforce, unavailability of products and supplies used in operations, and the decline in value of assets held by the Company. Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock-based compensation, valuation of derivative liabilities and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made. Net Loss per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 4,898,092 for the three months ended March 31, 2020. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 5,150,000 for the three months ended March 31, 2019. Common stock equivalents are included in the diluted income per share calculation only when option or warrant exercise prices are lower than the average market price of the common shares for the period presented. One hundred thousand (100,000) options and two hundred and fifty thousand (250,000) warrants were not included in the calculation of net loss per common share for the three months ended March 31, 2020 and One hundred thousand (100,000) options were not included in the calculation of net loss per common share for the three months ended March 31, 2019 because their effect would be anti-dilutive. Research and Development In accordance with FASB ASC 730, Research and Development Recently Issued Authoritative Guidance In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation is not needed until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s consolidated financial statements.

Going Concern and Management's

Going Concern and Management's Liquidity Plans	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Liquidity Plans	Note 3 – Going Concern and Management’s Liquidity Plans The Company’s condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying condensed consolidated financial statements, the Company has had a net loss from operations of $383,834 and $503,173 for the three months ended March 31, 2020 and 2019, respectively. The net cash used in operations were $349,072 and $473,259 for the three months ended March 31, 2020 and 2019, respectively. Additionally, the Company had an accumulated deficit of $8,803,920 at March 31, 2020 and has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management plans to raise additional capital through the sale of convertible debt securities offering. However, there are no assurances that such additional funding will be achieved. The Company does not have sufficient cash flow for the next twelve months from the issuance of these condensed consolidated financial statements. The Company’s history of recurring losses, and uncertainties as to whether its operations will become profitable and generate operating cash flows raise substantial doubt about its ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements The Company follows FASB ASC 820, Fair Value Measurements and Disclosures Level 1 - Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 - Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 - Pricing inputs that are generally unobservable inputs and not corroborated by market data. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts reported in the Company’s condensed consolidated financial statements for cash, accounts payable and accrued expenses approximate their fair value because of the immediate or short-term nature of these financial instruments. Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm's-length transactions unless such representations can be substantiated. The following table presents liabilities that are measured and recognized at fair value as of March 31, 2020 and December 31, 2019, on a recurring basis: March 31, 2020 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities $ — — 385,890 $ 385,890 December 31, 2019 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities $ — — 183,451 $ 183,451

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at March 31, 2020 and December 31, 2019 consisted of the following: March 31, 2020 December 31, 2019 Accounts payable and accrued expenses $ 284,031 $ 309,231 Accrued interest 100,128 79,964 Totals $ 384,159 $ 389,195

Payroll and Related Liabilities

Payroll and Related Liabilities	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Payroll and Related Liabilities	NOTE 6 – PAYROLL AND RELATED LIABILITIES Payroll and related liabilities at March 31, 2020 and December 31, 2019 consisted of the following: March 31, 2020 December 31, 2019 Payroll $ 30,000 $ — Payroll taxes 243,510 243,208 Totals $ 273,510 $ 243,208 As of the three months period ended March 31, 2020 and the year ended December 31, 2019, the Company has accrued payroll taxes in connection with salaries paid and accrued to four officers of the Company.

Loan Payable

Loan Payable	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Loan Payable	NOTE 7 – LOAN PAYABLE During the year ended December 31, 2017, the Company borrowed $367,500 and issued a promissory note with a maturity date of October 18, 2017. This note was later amended to extend the maturity to April 18, 2019. During the year ended December 31, 2018, the Company borrowed an additional $352,500 and issued a promissory note with a maturity date of April 18, 2019. These notes incurred 3% interest per annum. On June 29, 2018, these notes were amended to extend the maturity date to July 1, 2020 and the interest rate was changed to 8% per annum. All accrued interest prior to the amendment date was forgiven. Upon the consolidation of the Company and Kannalife, $100,000 of the above-mentioned borrowings was eliminated due to it being an intercompany transaction. The total, above mentioned, notes payable due is $620,000 as of March 31, 2020. Total interest expense on notes payable, amounted to $12,230 for the three months ended March 31, 2020 and 2019, respectively. Accrued interest related to these notes is $85,611 and $73,381 as of March 31, 2020 and December 31, 2019, respectively.

Loan Payable - Related Party

Loan Payable - Related Party	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Loan Payable - Related Party	NOTE 8 – LOAN PAYABLE – RELATED PARTY Prior to the share exchange agreement, the Company borrowed $25,822 and issued a promissory note with a maturity date of March 31, 2020. Additionally, the note holder advanced the Company $16,270 for working capital. The loans represent working capital advances from shareholders, bear interest at 0.5%, and grant a security interest in the Company’s assets as collateral. In March 2018, this note was amended, and the original note holder assigned the note to Kettner Investments, LLC, a significant shareholder. The note is now non-interest bearing. Accrued interest related to this note is $226 as of March 31, 2020 and December 31, 2019, respectively.

Capital Lease Obligations

Capital Lease Obligations	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Capital Lease Obligations	NOTE 9 – CAPITAL LEASE OBLIGATIONS In September 2019, the Company entered into a lease agreement with Thermo Fisher Scientific to acquire equipment with 48 monthly payments of $941, payable through September 1, 2023, with an effective interest rate of 12% per annum. The outstanding balance of this capital lease was $33,496, secured by equipment with carrying value of $56,982, as of March 31, 2020.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Convertible Notes Payable	NOTE 10 – CONVERTIBLE NOTES PAYABLE Prior to the Share Exchange, the Company issued a convertible note to an investor, face value of $500,000, in exchange for $500,000 in cash. The note is unsecured, bears interest at the rate of 3% per annum and matures on February 16, 2030. The note is convertible into common stock of the Company at $0.10 per share at any time at the option of the holder, subject to a 4.9% blocking provision which prohibits the holder from converting into common stock of the Company if such conversion results in the holder owning greater than 4.9% of the outstanding common stock of the Company after giving effect to the conversion. On September 26, 2019, the Company issued 1,500,000 shares of common stock for the conversion of $123,627 convertible notes payable and $26,373 of related accrued interest. The outstanding balance on this convertible note after the conversion was $376,373. In December 2019, the Company entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell to the investor a $100,000 convertible note bearing interest at 8% per annum (the “Note”). The Note matures two years from the date of issuance. The Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of 75% of the average closing price of the Company’s common stock on the fifteen days prior to conversion. The Company may not prepay this Note within the first six months. If, after the first six months until the maturity of the Note the Company: (a) elects to repay the Note, it must do so at a premium of one hundred and twenty five percent (125%) of the face amount of the Note, together with all unpaid and accrued interest to the date of repayment. (b) elects to involuntarily exercise conversion of this Note to the Holder, the Company must provide written notice to the Holder along with an executed copy of the Company’s Notice of Conversion, specifying that the Note shall be converted into shares of the Company’s Common Stock based upon at an effective conversion price of 75% of the average closing price of the Company’s common stock on the fifteen days prior to conversion. The embedded conversion feature of this Note was deemed to require bifurcation and liability classification, at fair value. Pursuant to the Securities Purchase Agreement, the Company also sold warrants to the investors to purchase up to an aggregate of 100,000 shares of common stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 12) resulting in full discount of the Note. On March 12, 2020, the Company entered into securities purchase agreements with two different accredited investors (each an “Investor”, and together the “Investors”) pursuant to which each Investor purchased an 8% unsecured convertible promissory note (each a “Note”, and together the “Notes”) from the Company. The terms and conditions of each of the Notes are substantially the same. Each Note has a principal amount of $105,000 less a $5,000 original issue discount for a purchase price of $100,000, with a maturity date of March 12, 2021. All principal amounts and the interest thereon are convertible into shares of the Company’s common stock at the option of each Investor, after six (6) months from the date of the Notes. These Notes have a variable conversion price and the Company recorded embedded derivative liabilities. Total interest expense on convertible notes payable, inclusive of amortization of debt discount of $29,589 and $0, amounted to $32,522 and $3,750 for the three months ended March 31, 2020 and 2019, respectively.

Convertible Notes Payable - Rel

Convertible Notes Payable - Related Party	3 Months Ended
	Mar. 31, 2020
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]
Convertible Notes Payable - Related Party	NOTE 11 – CONVERTIBLE NOTES PAYABLE – RELATED PARTY In January 2020, the Company sold an additional $100,000, to Kettner Investments, LLC, a significant shareholder, under the Note and sold warrants to purchase up to an aggregate of 100,000 shares of common stock to an investor under the Securities Purchase Agreement. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 12) resulting in full discount of the Note. In February 2020, the Company sold an additional $50,000, to the CEO of MJNA, a significant shareholder, under the Note and sold warrants to purchase up to an aggregate of 50,000 shares of common stock to an investor under the Securities Purchase Agreement. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 12) resulting in full discount of the Note. Total interest expense on convertible notes payable – related party, inclusive of amortization of debt discount of $14,521 and $0, amounted to $16,698 and $0 for three months ended March 31, 2020 and 2019, respectively.

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Derivative Liabilities	NOTE 12 – DERIVATIVE LIABILITIES The Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. In addition, the Company issued warrants with variable conversion provisions. The conversion terms of the convertible notes and warrants are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. Based on the various convertible notes described in Note 10 and 11, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows for the three months ended March 31, 2020: Derivative Liability - Convertible Notes Derivative Liability - Warrants Total Balance as of December 31, 2019 $ 61,430 $ 122,021 $ 183,451 Additions during the period 317,034 176,570 493,604 Change in fair value (97,232 ) (193,933 ) (291,165 ) Change due to exercise / redemptions — — — Balance as of March 31, 2020 $ 281,232 $ 104,658 $ 385,890 The fair value of the derivative liability – convertible notes is estimated using a Monty Carlo Pricing Model with the following assumptions: Market value of common stock $0.58 - 1.80 Expected volatility 100.9% - 146.7% Expected term (in years) 0.73 – 2 Risk-free interest rate 1.98% - 2.08% The fair value of the derivative liability – warrants is estimated using a Monty Carlo Pricing Model with the following assumptions: Market value of common stock $0.58 Expected volatility 147% Expected term (in years) 2.73 - 2.84 Risk-free interest rate 0.27% - 0.55%

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 13 – COMMITMENTS AND CONTINGENCIES Legal Proceedings From time to time the Company may get involved in legal proceedings arising in the ordinary course of business. Other than as set forth in “Legal Proceedings” in Part II below, the Company believes there is no litigation pending that could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition. Occupancy Leases On April 1, 2014, the Company entered into a one year lease arrangement for office space, with the option to renew the lease annually. The lease has been renewed through April 2021. The monthly rent payment is $5,400 and the security deposit is $15,000.

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Deficit	NOTE 14 – STOCKHOLDERS’ DEFICIT Series A Preferred Stock Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share. Series B Preferred Stock Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series B Preferred Stock. Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Company’s board of directors and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share. Common Stock The Company is authorized to issue 200,000,000 shares of $0.0001 par value common stock. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders. As of March 31, 2020 and December 31, 2019, there were 74,225,141 shares of common stock issued and outstanding, respectively. Stock Options On September 1, 2017, the Company entered into an agreement for consulting services. As compensation the Company granted options to purchase 100,000 shares of common stock at a price of $2.00 per share and are exercisable for five years. The stock option vests in equal monthly installments of 24 months. These options were valued at $20,154 using a Black-Scholes Options Pricing Model. For the three months ended March 31, 2020 and 2019, the Company recorded $0 and $2,519, respectively, as stock based compensation which is included in the general and administrative expenses in the condensed consolidated statement of operations. The remaining compensation expense outstanding for future periods is $0. The fair value of the options is estimated using a Black-Scholes Options Pricing Model with the following assumptions: Market value of common stock on issuance date $ 0.40 Exercise price $ 2.00 Expected volatility 100 % Expected term (in years) 5 Risk-free interest rate 1.73 % Expected dividend yields — On August 14, 2019, the Board authorized the Kannalife, Inc. 2019 Equity Incentive Plan (the “2019 Plan”) in order to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and consultants of our company and certain of its affiliates and to enable our company and certain of its affiliates to obtain and retain services of these individuals, which is essential to our long-term success. Our 2019 Plan allows for the grant of a variety of equity vehicles to provide flexibility in implementing equity awards, including incentive stock options, non-qualified stock options, restricted stock grants, unrestricted stock grants and restricted stock units. Authorized Shares. A total of 7,500,000 shares of common stock were authorized under the 2019 Plan for which as of March 31, 2020 a total of 100,000 are outstanding. See Note 16 for subsequent issuances. Warrants In December 2019, the Company entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell the investor a $100,000 convertible note bearing interest at 8% per annum (the “Note”). The Company also sold warrants to the investors to purchase up to an aggregate of 100,000 shares of common stock at a per share purchase price of one hundred twenty five percent (125%) of the voluntary or involuntary conversion price of the Company’s 8% convertible note. The warrant is fully vested and was fully expensed as of the issuance date with an exercise term of three (3) years. See Note 10. In January and February 2020, the Company entered into a Securities Purchase Agreement with investors pursuant to which the Company agreed to sell the investors a $100,000 and $50,000 convertible note bearing interest at 8% per annum (the “Note”), respectively. The Company also sold warrants to the investors to purchase up to an aggregate of 100,000 and 50,000 shares of common stock, respectively, at a per share purchase price of one hundred twenty five percent (125%) of the voluntary or involuntary conversion price of the Company’s 8% convertible note. The warrants are fully vested and was fully expensed as of the issuance date with an exercise term of three (3) years. See Note 11. The following is a summary of outstanding and exercisable warrants: Number of Shares Weighted Average Exercise Price Balance at December 31, 2019 100,000 $ 3.26 Issued 150,000 2.27 Expired — — Balance at March 31, 2020 250,000 $ 0.63 At March 31, 2020, 250,000 warrants for common stock were exercisable and the intrinsic value of these warrants was $29,939. At March 31, 2020, the weighted average remaining contractual life was 2.75 years for warrants outstanding.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 15 – RELATED PARTY TRANSACTIONS The Company’s Chief Executive Officer (“CEO”) shares the use of the leased office space for personal living quarters. The CEO reimburses the Company for 50% of the monthly rent, or $2,700 per month. As of March 31, 2020, the Company owes the CEO $49,261 for expenses the CEO incurred on behalf of the Company. See Notes 8 and 11 for additional related party transactions.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 16 – SUBSEQUENT EVENTS On April 23, 2020, the Company received a loan from PNC Bank (the “Lender”) in the amount of $84,200, pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted March 27, 2020. On April 28, 2020, the Company executed an intellectual property rights purchase and transfer agreement whereby this agreement grants certain IP to the Company. In connection with the execution of this agreement, the Company issued 25,000 shares of the Company’s common stock to the research organization. On May 4, 2020, the Company granted 4,850,000 options to purchase shares of the Company’s common stock at an exercise price of $0.57 per share to certain directors and employees of the Company (including our named executive officers). One quarter of these options vest on the grant day, and the remainder of the options vest equally over thirty six (36) months starting January 1, 2020.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP.
Significant risks and uncertainties	Significant Risks and Uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. In December 2019, a novel strain of coronavirus surfaced. The spread of COVID-19 around the world in the first quarter of 2020 has caused significant volatility in U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations. The Company’s operations as of March 31, 2020 have not been affected, but may be affected in the future, by the recent and ongoing outbreak of the coronavirus disease 2019 (COVID-19) which in March 2020, was declared a pandemic by the World Health Organization. The ultimate disruption which may be caused by the outbreak is uncertain; however, it may result in a material adverse impact on the Company’s financial position, operations and cash flows. Possible areas that may be affected include, but are not limited to, disruption to the Company’s labor workforce, unavailability of products and supplies used in operations, and the decline in value of assets held by the Company.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock-based compensation, valuation of derivative liabilities and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 4,898,092 for the three months ended March 31, 2020. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 5,150,000 for the three months ended March 31, 2019. Common stock equivalents are included in the diluted income per share calculation only when option or warrant exercise prices are lower than the average market price of the common shares for the period presented. One hundred thousand (100,000) options and two hundred and fifty thousand (250,000) warrants were not included in the calculation of net loss per common share for the three months ended March 31, 2020 and One hundred thousand (100,000) options were not included in the calculation of net loss per common share for the three months ended March 31, 2019 because their effect would be anti-dilutive.
Research and Development	Research and Development In accordance with FASB ASC 730, Research and Development
Recently Issued Authoritative Guidance	Recently Issued Authoritative Guidance In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation is not needed until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s consolidated financial statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis	The following table presents liabilities that are measured and recognized at fair value as of March 31, 2020 and December 31, 2019, on a recurring basis: March 31, 2020 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities $ — — 385,890 $ 385,890 December 31, 2019 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities $ — — 183,451 $ 183,451

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at March 31, 2020 and December 31, 2019 consisted of the following: March 31, 2020 December 31, 2019 Accounts payable and accrued expenses $ 284,031 $ 309,231 Accrued interest 100,128 79,964 Totals $ 384,159 $ 389,195

Payroll and Related Liabiliti_2

Payroll and Related Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Schedule Of Payroll and Related Liabilities	Payroll and related liabilities at March 31, 2020 and December 31, 2019 consisted of the following: March 31, 2020 December 31, 2019 Payroll $ 30,000 $ — Payroll taxes 243,510 243,208 Totals $ 273,510 $ 243,208

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Schedule of Derivative Liabilities	Based on the various convertible notes described in Note 10 and 11, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows for the three months ended March 31, 2020: Derivative Liability - Convertible Notes Derivative Liability - Warrants Total Balance as of December 31, 2019 $ 61,430 $ 122,021 $ 183,451 Additions during the period 317,034 176,570 493,604 Change in fair value (97,232 ) (193,933 ) (291,165 ) Change due to exercise / redemptions — — — Balance as of March 31, 2020 $ 281,232 $ 104,658 $ 385,890
Warrants
Schedule of share-based payment award, stock options, valuation assumptions	The fair value of the derivative liability – warrants is estimated using a Monty Carlo Pricing Model with the following assumptions: Market value of common stock $0.58 Expected volatility 147% Expected term (in years) 2.73 - 2.84 Risk-free interest rate 0.27% - 0.55%
Convertible Notes
Schedule of share-based payment award, stock options, valuation assumptions	The fair value of the derivative liability – convertible notes is estimated using a Monty Carlo Pricing Model with the following assumptions: Market value of common stock $0.58 - 1.80 Expected volatility 100.9% - 146.7% Expected term (in years) 0.73 – 2 Risk-free interest rate 1.98% - 2.08%

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2020
Schedule of outstanding and exercisable warrants	The following is a summary of outstanding and exercisable warrants: Number of Shares Weighted Average Exercise Price Balance at December 31, 2019 100,000 $ 3.26 Issued 150,000 2.27 Expired — — Balance at March 31, 2020 250,000 $ 0.63
Option [Member]
Schedule of share-based payment award, stock options, valuation assumptions	The fair value of the options is estimated using a Black-Scholes Options Pricing Model with the following assumptions: Market value of common stock on issuance date $ 0.40 Exercise price $ 2.00 Expected volatility 100 % Expected term (in years) 5 Risk-free interest rate 1.73 % Expected dividend yields —

Organization and Nature of Op_2

Organization and Nature of Operations (Details Narrative)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of Incorporation	Mar. 25, 2013

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accounting Policies [Abstract]
Weighted average number of common stock, anti-dilutive	4,898,092	5,150,000
Research and Development	$ 19,727	$ 101,278

Going Concern and Management'_2

Going Concern and Management's Liquidity Plans (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss from operations	$ (383,834)	$ (503,173)
Net cash used in operating activities	(349,072)	$ (473,259)
Accumulated deficit	$ (8,803,920)		$ (8,496,088)

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Derivative liabilities	$ 385,890	$ 183,451
Level 1
Derivative liabilities	0	0
Level 2
Derivative liabilities	0	0
Level 3
Derivative liabilities	385,890	183,451
Total Carrying Value
Derivative liabilities	$ 385,890	$ 183,451

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 284,031	$ 309,231
Accrued interest	100,128	79,964
Totals	$ 384,159	$ 389,195

Payroll and Related Liabiliti_3

Payroll and Related Liabilities - Schedule Of Accrued Payroll And Payroll Taxes (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accrued Payroll And Payroll Taxes - Schedule Of Accrued Payroll And Payroll Taxes
Payroll	$ 30,000	$ 0
Payroll taxes	243,510	243,208
Totals	$ 273,510	$ 243,208

Loan Payable (Details Narrative

Loan Payable (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 30, 2019	Dec. 30, 2018	Dec. 30, 2017	Dec. 31, 2019	Jun. 29, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Promissory note value				$ 352,500	$ 367,500
Interest rate						3.00%	8.00%	3.00%
Maturity date				Jul. 1, 2020	Jul. 1, 2020
Accrued interest	$ 85,611		$ 73,381
Loan payable - long term	620,000					$ 620,000
Interest expense	$ 12,230	$ 12,230

Loan Payable - Related Party (D

Loan Payable - Related Party (Details Narrative) - USD ($)	7 Months Ended	12 Months Ended
	Jul. 25, 2018	Dec. 30, 2018	Dec. 30, 2017	Mar. 31, 2020	Dec. 31, 2019	Jun. 29, 2018	Dec. 31, 2017
Maturity date		Jul. 1, 2020	Jul. 1, 2020
Interest rate					3.00%	8.00%	3.00%
Advanced from related party				$ 49,261	$ 25,349
Related Party Promissory Note
Note payable, related party	$ 25,822
Maturity date	Mar. 31, 2020
Interest rate	0.05%
Accrued interest, related party note				$ 226	$ 226
Advanced from related party	$ 16,270

Capital Lease Obligations (Deta

Capital Lease Obligations (Details Narrative) - USD ($)	1 Months Ended
	Sep. 30, 2019	Mar. 31, 2020
Debt Disclosure [Abstract]
Effective interest rate		12.00%
Monthly payment	$ 941
Capital Lease Obligations		$ 33,496
Equipment with carrying value		$ 56,982

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Mar. 12, 2020	Sep. 26, 2019	Jun. 29, 2018	Dec. 31, 2017	Jul. 24, 2015
Convertible debt		$ 376,373
Interest rate	3.00%					8.00%	3.00%
Common stock issued	74,225,141	74,225,141
Amortization of debt discount		$ 44,109	$ 0
Securities Purchase Agreement [Member]
Number of warrants sold	100,000
Proceeds from sale of warrants	$ 100,000
Interest rate	8.00%
Convertible Debt
Convertible debt				$ 105,000				$ 500,000
Maturity date				Mar. 12, 2021				Feb. 16, 2030
Interest rate				8.00%				3.00%
Convertible price per share								$ 0.10
Original issue discount				$ 5,000
Purchase price				$ 100,000
Common stock issued					1,500,000
Value of notes converted					$ 123,627
Accrued interest					$ 26,373
Interest expense		32,522	3,750
Amortization of debt discount		$ 29,589	$ 0

Convertible Notes Payable - R_2

Convertible Notes Payable - Related Party (Details Narrative) - USD ($)	1 Months Ended			3 Months Ended
	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Amortization of debt discount				$ 44,109	$ 0
Convertible Notes Payable Related Party [Member]
Interest expense				16,698	0
Amortization of debt discount				$ 14,521	$ 0
Securities Purchase Agreement [Member]
Number of warrants sold			100,000
Proceeds from sale of warrants			$ 100,000
Securities Purchase Agreement [Member] | Kettner Investments
Number of warrants sold		100,000
Proceeds from sale of warrants		$ 100,000
Securities Purchase Agreement [Member] | Chief Executive Officer
Number of warrants sold	50,000
Proceeds from sale of warrants	$ 50,000

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance at beginning	$ 183,451
Additions during the period	493,604
Change in fair value	291,165	$ 0
Change due to exercise / redemptions
Balance at end	385,890
Convertible Notes
Balance at beginning	122,021
Additions during the period	176,570
Change in fair value	(193,933)
Change due to exercise / redemptions
Balance at end	104,658
Warrants
Balance at beginning	61,430
Additions during the period	317,034
Change in fair value	(97,232)
Change due to exercise / redemptions
Balance at end	$ 281,232

Derivative Liabilities - Assump

Derivative Liabilities - Assumptions - Convertible notes (Details) - Convertible Notes	3 Months Ended
	Mar. 31, 2020$ / shares
Minimum [Member]
Market value of common stock	$ 0.58
Expected volatility	100.90%
Expected term (in years)	8 months 23 days
Risk-free interest rate	1.98%
Maximum [Member]
Market value of common stock	$ 1.80
Expected volatility	146.70%
Expected term (in years)	2 years
Risk-free interest rate	2.08%

Derivative Liabilities - Assu_2

Derivative Liabilities - Assumptions - Warrants (Details) - Warrants	3 Months Ended
	Mar. 31, 2020$ / shares
Market value of common stock	$ 0.58
Expected volatility	147.00%
Minimum [Member]
Expected term (in years)	2 years 8 months 23 days
Risk-free interest rate	0.27%
Maximum [Member]
Expected term (in years)	2 years 10 months 3 days
Risk-free interest rate	0.55%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Apr. 01, 2014
Security Deposit	$ 17,121	$ 17,121
Office Space
Monthly Rent			$ 5,400
Security Deposit			$ 15,000

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of share-based payment award, stock options, valuation assumptions (Details) - Option [Member]	3 Months Ended
	Mar. 31, 2020$ / shares
Market value of common stock on issuance date	$ 0.4
Exercise price	$ 2
Expected volatility	100.00%
Expected term (in years)	5 years
Risk-free interest rate	1.73%
Expected dividend yields	0.00%

Stockholders' Deficit - Summary

Stockholders' Deficit - Summary of outstanding and exercisable warrants (Details) - Warrants	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of Warrants
Number of Warrants Outstanding, Beginning | shares	100,000
Number of Warrants Issued | shares	150,000
Number of Warrants Expired | shares	0
Number of Warrants Outstanding, Ending | shares	250,000
Weighted Average Exercise Price
Weighted Average Exercise Price Outstanding, Beginning | $ / shares	$ 3.26
Weighted Average Exercise Price Issued | $ / shares	2.27
Weighted Average Exercise Price Expired | $ / shares	.00
Weighted Average Exercise Price Outstanding, Ending | $ / shares	$ 0.63

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Sep. 01, 2017	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Preferred Stock, Par or Stated Value Per Share				$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized				5,000,000	5,000,000
Common Stock Description					All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative, and therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders.
Common Stock, Par or Stated Value Per Share				$ 0.0001	$ 0.0001
Common Stock, Shares Authorized				200,000,000	200,000,000
Common Stock, Shares, Issued				74,225,141	74,225,141
Common Stock, Shares, Outstanding				74,225,141	74,225,141
Options granted	100,000
Options granted, exercise price	$ 2
Vesting period	5 years
Value of option	$ 20,154
Unrecognized compensation expense					$ 0
Common stock authorized under plan					7,500,000
Warrant Exercisable					250,000
Intrinsic value of warrants					$ 29,939
Weighted average remaining contractual life of warrants outstanding					2 years 9 months
Securities Purchase Agreement [Member]
Number of warrants sold				100,000
Proceeds from sale of warrants				$ 100,000
Interest rate				8.00%
Warrant term				3 years
Securities Purchase Agreement [Member] | Kettner Investments
Number of warrants sold			100,000
Proceeds from sale of warrants			$ 100,000
Interest rate			8.00%
Warrant term			3 years
Securities Purchase Agreement [Member] | Chief Executive Officer
Number of warrants sold		50,000
Proceeds from sale of warrants		$ 50,000
Interest rate		8.00%
Warrant term		3 years
Series A Preferred Stock [Member]
Preferred stock description					Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share, and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors, and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share.
Preferred Stock, Shares Authorized				75	75
Series B Preferred Stock [Member]
Preferred stock description					Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series B Preferred Stock. Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share, and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Company’s board of directors, and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share.
Preferred Stock, Shares Authorized				75	75
2019 Plan [Member]
Common Stock, Shares, Outstanding					100,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	3 Months Ended
	Mar. 31, 2020USD ($)
Chief Executive Officer
Related party cost	$ 49,261

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 04, 2020	Sep. 01, 2017	Apr. 28, 2020	Apr. 23, 2020
Options granted		100,000
Subsequent Event [Member]
Stock issued for purchase of intellectual property			25,000
Subsequent Event [Member] | PNC Bank [Member]
Proceeds from loan				$ 84,200
Subsequent Event [Member] | Executive Officers [Member]
Options granted	4,850,000
Share Price	$ 0.57